Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Increased to $920.00 by Analysts at Argus

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective boosted by Argus from $825.00 to $920.00 in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the company. VNET Group restated a downgrade rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 28th. Wells Fargo & Company increased their price target on Regeneron Pharmaceuticals from $875.00 to $980.00 and gave the stock an overweight rating in a report on Monday, August 21st. Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $897.00 to $912.00 and gave the stock an overweight rating in a report on Friday, August 4th. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a hold rating to a buy rating and increased their target price for the stock from $720.00 to $992.00 in a report on Monday, August 21st. Finally, 22nd Century Group reiterated a downgrade rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 28th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $904.00.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $824.51 on Friday. The company has a market capitalization of $89.51 billion, a PE ratio of 21.80, a P/E/G ratio of 2.47 and a beta of 0.19. The company has a 50 day simple moving average of $784.26 and a two-hundred day simple moving average of $774.72. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.64 and a current ratio of 5.45. Regeneron Pharmaceuticals has a fifty-two week low of $668.00 and a fifty-two week high of $847.50.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $10.24 earnings per share for the quarter, beating analysts’ consensus estimates of $8.48 by $1.76. The business had revenue of $3.16 billion during the quarter, compared to the consensus estimate of $3.02 billion. Regeneron Pharmaceuticals had a net margin of 33.93% and a return on equity of 19.19%. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $9.77 EPS. Research analysts anticipate that Regeneron Pharmaceuticals will post 35.42 earnings per share for the current year.

Insider Activity

In related news, EVP Marion Mccourt sold 250 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $710.09, for a total value of $177,522.50. Following the completion of the sale, the executive vice president now owns 20,303 shares of the company’s stock, valued at approximately $14,416,957.27. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $736.59, for a total value of $73,659.00. Following the completion of the transaction, the director now owns 18,647 shares in the company, valued at approximately $13,735,193.73. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Marion Mccourt sold 250 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $710.09, for a total value of $177,522.50. Following the completion of the transaction, the executive vice president now owns 20,303 shares of the company’s stock, valued at approximately $14,416,957.27. The disclosure for this sale can be found here. Insiders sold a total of 32,521 shares of company stock valued at $27,232,176 in the last ninety days. 8.83% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in REGN. Bank Julius Baer & Co. Ltd Zurich boosted its stake in Regeneron Pharmaceuticals by 91,386.5% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 74,501,081 shares of the biopharmaceutical company’s stock worth $53,532,007,000 after purchasing an additional 74,419,647 shares during the period. EP Wealth Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $434,000. Envestnet Asset Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 2,719.2% during the 1st quarter. Envestnet Asset Management Inc. now owns 1,916,774 shares of the biopharmaceutical company’s stock valued at $50,488,000 after acquiring an additional 1,848,784 shares during the last quarter. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $697,296,000. Finally, Capital International Investors boosted its position in shares of Regeneron Pharmaceuticals by 37.3% during the 2nd quarter. Capital International Investors now owns 2,956,615 shares of the biopharmaceutical company’s stock valued at $2,124,326,000 after acquiring an additional 803,143 shares during the last quarter. Institutional investors own 84.15% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.